Bluebird Bio shares pop on what CEO calls ‘very exciting’ cancer news
June 05, 2017 at 17:28 PM EDT
Bluebird Bio CEO Nick Leschly said the multiple myeloma patients in a study have had an "incredible response rate."
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|